Medical Bulletin 11/April/2026

Here are the top medical news for today:

New Study Highlights Brain Benefits of High-Quality Plant-Based Diets

Not all plant-based diets are healthy—and your brain may know the difference.

A new study published in Neurology journal finds that the quality of plant-based foods you eat could significantly influence your risk of Alzheimer’s disease and other dementias. While plant-based eating is often seen as beneficial, researchers say it’s not just about eating plants—but choosing the right ones.

The study, led by scientists from University of Hawaii at Manoa, followed 92,849 adults with an average age of 59 over 11 years. During this time, more than 21,000 participants developed dementia. Researchers analyzed dietary patterns by categorizing them into three types: an overall plant-based diet, a healthful plant-based diet, and an unhealthful plant-based diet.

The healthful version emphasized whole grains, fruits, vegetables, nuts, legumes, and healthy oils. In contrast, the unhealthful version included refined grains, sugary foods, fruit juices, and processed plant-based items.

Results showed that participants who consumed the highest amount of plant foods overall had a 12% lower risk of dementia compared to those who consumed the least. Those following a healthful plant-based diet had a 7% lower risk. However, people consuming the unhealthiest plant-based foods had a 6% higher risk of developing dementia.

Long-term changes in diet also mattered. Among participants tracked over time, those who shifted toward unhealthful plant-based diets had a 25% higher risk of dementia. Conversely, those who moved away from unhealthy choices reduced their risk by 11%.

The findings highlight a key message: simply avoiding animal products is not enough. Diet quality plays a crucial role in brain health. While the study is observational and does not prove cause and effect, it suggests that choosing nutrient-rich, minimally processed plant foods may support cognitive health as we age.

REFERENCE: Song-Yi Park, Veronica Wendy Setiawan, Eileen M. Crimmins, et al.; Plant-Based Dietary Patterns and Risk of Alzheimer Disease and Related Dementias in the Multiethnic Cohort Study; Neurology, The American Academy of Neurology; https://doi.org/10.1212/WNL.0000000000214916

Non-Invasive Urine Test Improves Prediction of Bladder Cancer Treatment Outcomes: Study

A simple urine sample may soon reveal whether bladder cancer will return—before scans can even detect it.

Bladder cancer, particularly non-muscle invasive bladder cancer (NMIBC), is one of the most commonly diagnosed cancers and is notorious for coming back even after early treatment. Patients typically undergo tumor removal followed by immunotherapy using BCG. However, doctors have long lacked a reliable way to predict who will benefit from this therapy and who will relapse.

Now, a new study published in Cell by researchers at Stanford University offers a promising solution: a highly sensitive, non-invasive urine test that can detect microscopic traces of tumor DNA and predict recurrence risk with remarkable accuracy.

The innovation lies in overcoming a major challenge in liquid biopsy testing. Scientists discovered that even healthy bladder cells can carry mutations—termed “clonal cystopoiesis”—which can lead to false positives. To address this, the team developed a statistical method to filter out these background mutations, allowing the test to distinguish real cancer signals from harmless genetic noise.

When tested in patients undergoing surgery and BCG therapy, the results were striking. Individuals with detectable tumor DNA after treatment had an almost certain risk of recurrence, while those whose tumor DNA disappeared showed excellent outcomes. In many cases, the test identified relapse risk even before standard cystoscopy exams showed abnormalities.

Researchers also identified three response patterns: patients cured by surgery alone, those who responded to BCG, and those who did not respond to either. This insight could help doctors tailor treatment strategies more precisely.

If validated in larger trials, this approach could transform bladder cancer care—reducing unnecessary treatments, prioritizing high-risk patients, and enabling earlier intervention. Ultimately, it moves the field closer to truly personalized cancer therapy, guided by a simple urine test.

REFERENCE: Shi, W. Y., et al. (2026). Field-effect-informed urine liquid biopsy for bladder cancer. Cell. DOI: 10.1016/j.cell.2025.12.054. https://www.cell.com/cell/abstract/S0092-8674(25)01503-X

Scientists Discover Brain Mechanism That Signals the Body to Stop Eating

What if the key to feeling full isn’t just in your neurons—but in overlooked brain cells working behind the scenes?

A new study published in Proceedings of the National Academy of Sciences is reshaping how scientists understand appetite control, revealing that astrocytes—once thought to be mere support cells—play an active role in telling the brain when to stop eating.

The research, led by teams from the University of Concepción and the University of Maryland, uncovers a previously unknown communication pathway in the hypothalamus, the brain’s hunger-regulating center.

Traditionally, neurons were considered the main players in signaling hunger and fullness. However, this study shows a more complex chain of events involving multiple cell types. After a meal, rising glucose levels are detected by specialized cells called tanycytes. These cells convert glucose into lactate, which then acts as a signaling molecule.

Instead of communicating directly with neurons, lactate first activates nearby astrocytes through a receptor known as HCAR1. Once activated, astrocytes release glutamate, a neurotransmitter that signals appetite-suppressing neurons, ultimately creating the sensation of fullness. In simple terms, tanycytes “talk” to astrocytes, and astrocytes “talk” to neurons.

Researchers also found that this signaling can spread across networks of astrocytes, amplifying the brain’s response to food intake. Interestingly, lactate may have a dual role—indirectly activating fullness signals while also potentially suppressing hunger signals through other pathways.

Scientists are now exploring whether manipulating the HCAR1 receptor could influence eating behavior. If successful, this pathway could complement existing treatments like Ozempic, offering a new frontier in metabolic health.

REFERENCE: S. López,R. Elizondo-Vega,V. Azócar,V. Sepúlveda,V. Opazo-Mellado,W. Vásquez,J.C. Sáez,R.C. Araneda, & M.D.L.Á. García-Robles, Tanycyte-derived lactate activates astrocytic HCAR1 to modulate glutamatergic signaling and POMC neuron excitability, Proc. Natl. Acad. Sci. U.S.A. 123 (15) e2537810123, https://doi.org/10.1073/pnas.2537810123 (2026).